Andhra Pradesh MedTech Zone (AMTZ) has launched a dedicated capital fund aimed at scaling promising medtech innovations and supporting early-to-mid-stage startups. The fund will provide equity investments, grants, and patient capital to help Indian medtech companies move from prototype to commercialization, focusing on affordable diagnostics, surgical devices, implants, and digital health solutions to strengthen domestic manufacturing and global competitiveness.
Glimpse:
The AMTZ Capital Fund targets ₹500–1,000 crore in initial corpus (with phased contributions from government, industry partners, and institutional investors) to back 50–100 medtech startups over the next 5 years. It offers flexible financing from seed to Series A along with access to AMTZ’s world-class testing labs, regulatory guidance, manufacturing support, and market access networks. The initiative prioritizes innovations addressing national health priorities like maternal health, infectious diseases, oncology, and rural diagnostics, with a goal to create high-skill jobs and reduce India’s reliance on imported medical devices.
The Andhra Pradesh MedTech Zone (AMTZ) has officially launched a dedicated capital fund to fuel the growth of India’s medtech sector and help innovative startups scale from early prototypes to market-ready products. The announcement was made on February 27, 2026, by senior AMTZ officials during a special event at the Vizag campus, attended by representatives from the Department for Promotion of Industry and Internal Trade (DPIIT), Invest India, leading medtech companies, and startup founders. The fund is designed to bridge the critical financing gap that many Indian medtech innovators face after initial R&D and proof-of-concept stages.
With an initial targeted corpus of ₹500–1,000 crore (to be built through government seed capital, contributions from industry partners, institutional investors, and international development funds), the AMTZ Capital Fund will provide a mix of equity investments, convertible grants, and patient capital tailored to the long development cycles typical in medical devices and diagnostics. Investments will range from ₹5 crore to ₹50 crore per company, targeting 50–100 startups over the next five years. Priority sectors include affordable diagnostics, point-of-care devices, surgical instruments, implants, biomedical wearables, and AI/ML-enabled health solutions that address India’s unique healthcare challenges.
The fund offers more than just capital participants will gain exclusive access to AMTZ’s unparalleled ecosystem, including ISO-certified testing labs, regulatory support for CDSCO approvals and international certifications, shared manufacturing facilities, clinical validation networks, and market access assistance through partnerships with hospitals, diagnostic chains, and government procurement programs. Startups will also receive mentorship from seasoned medtech entrepreneurs, technical guidance from AMTZ’s in-house experts, and opportunities for co-development with global players. The initiative aligns closely with national priorities under the National Medical Devices Policy 2023, PLI scheme, and Make in India, aiming to increase domestic value addition and exports while reducing India’s 70–80% dependence on imported medical devices.
AMTZ CEO Dr. Jitendra Sharma emphasized that the fund is not just about financial support but about creating a complete “innovation-to-market” pipeline that de-risks the journey for medtech entrepreneurs. Early focus will be on innovations addressing high-burden areas such as maternal and child health, infectious diseases, oncology diagnostics, and rural point-of-care testing. The first cohort of investee companies is expected to be selected within the next 6–9 months, with several promising startups already in discussions.
This launch positions AMTZ as a comprehensive enabler of India’s medtech ecosystem combining world-class infrastructure, regulatory facilitation, clinical validation, and now dedicated capital to help the country emerge as a global leader in affordable, innovative medical technologies. The fund is expected to create thousands of high-skill jobs, attract international co-investors, and generate significant economic and health impact over the coming decade.
“Medtech startups in India often succeed in innovation but struggle with scaling. With this dedicated capital fund, AMTZ is removing that barrier turning great ideas into life-saving products that reach every corner of the country and the world.”
By
HB Team
Related News
